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Abstract
Cytotoxic T-lymphocytes (CTL) kill their targets by cytolytic granule secre-
tion at the immunological synapse. The Sec/Munc protein, Munc18-2,
and its binding partner Syntaxin 11 (STX11) are both required for gran-
ule secretion, with mutations in either leading to the primary immun-
odeﬁciency, Familial Haemophagocytic Lymphohistiocytosis (FHL4 and
5). Understanding how Munc18-2 and STX11 function in CTL has
been hampered by not knowing the endogenous localization of these
proteins. Using a novel FHL5 Munc18-2 mutation that results in loss
of protein, cytotoxicity and degranulation together with CTL from an
FHL4 patient lacking STX11, enabled us to localize endogenous STX11
and Munc18-2 in CTL. Munc18-2 localized predominantly to cytolytic
granules with low levels associated with the plasma membrane where
STX11 localized. Importantly, while Munc18-2 localization is unaffected
by the absence of STX11 in FHL4 CTL, STX11 is lost from the plasma
membrane in FHL5 CTL lacking Munc18-2. These ﬁndings support a role
for Munc18-2 in chaperoning STX11 to the plasmamembrane where the
ﬁnal fusion events involved in secretion occur.
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CD8-positive cytotoxic T-lymphocytes (CTL) are key
players of the mammalian immune system, providing pro-
tection from viral infection and cancerous cells. CTL kill
through precise delivery of perforin and granzymes across
a highly organized CTL:target interface that is known as
the immune synapse. CTL protect themselves from the
potent pro-apoptotic factors by storing these proteins in
specialized secretory lysosomes, termed cytolytic granules.
During CTL attack, these granules are delivered to the
synapse where they fuse with the plasma membrane and
release their deadly contents onto the target (reviewed in 1).
The biogenesis of cytolytic granules and their final fusion
with the plasma membrane requires a specialized fusion
machinery. Two components of this are the SNAP (Solu-
ble NSF Attachment Protein) Receptor (SNARE)-protein
Syntaxin 11 (STX11) (2) and the Syntaxin binding pro-
tein Munc18-2 (3,4) and genetic mutations that cause loss
of function of either of these proteins gives rise to Famil-
ial Haemophagocytic Lymphohistiocytosis (FHL), a devas-
tating autosomal hereditary immune deficiency condition
that is marked by the failure of CTL to kill infected cells
efficiently (reviewed by 5,6).
In neuronal and epithelial cells, Munc18 proteins were
found to be required for stable plasma membrane localiza-
tion of Syntaxin 1A (STX1A) (7,8). Interestingly, in FHL5
patient CTL (in which Munc18-2 is lost) STX11 levels
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are usually strongly reduced and the inability of STX11
and Munc18-2 deficient cells to kill target cells efficiently
was shown to be due to a degranulation defect (3,4,9).
This led to the suggestion that a chaperoning interac-
tion similar to the Munc18/STX1A pair is given between
Munc18-2 and STX11 and that the two proteins drive the
last step of granule secretion at the CTL plasma mem-
brane (3,4,9–12). Notably, the finding that FHL5 patients
with mutations R65Q/W retain the ability to interact with
STX11 supports an additional direct role in secretion for
Munc18-2 (13).WhetherMunc18-2 and STX11 function at
the plasma membrane, or at a late granule maturation step
(14) remains unclear, in part due to the lack of information
on the precise localization of these proteins.
STX11 and Munc18-2 are widely expressed (15–17) and
studies in other secretory cells flagged up several roles
for Munc18-2 on compartments other than the plasma
membrane. In mast cells, Munc18-2 on the limiting mem-
brane of secretory granules appeared to provide a link
to microtubules and thus promote the transport of gran-
ules to the cell periphery (18). A study in the pancre-
atic beta-cell line MIN6 reported a role for Munc18-2 in
modulating calcium responsiveness during the secretion
of granules. Sucrose gradient analysis detected Munc18-2
predominantly in low-density fractions that correspond to
‘small membranous organelles and soluble proteins’ (19).
Furthermore, it has been suggested that in CTL the gran-
ules themselves undergo one (or several) maturation steps
before they become ‘secretion competent bullets’ that carry
all the machinery required for fusion at the plasma mem-
brane (14). These reports highlight multiple potential roles
for Munc18-2 but exactly when and where STX11 and
Munc18-2 function in CTL is not fully understood.
Precise localization of proteins within the cellular envi-
ronment can give important clues about their function.
However, several issues have been reported previously
when it comes to the localization of tagged SNARE-protein
and Munc18-2 constructs: One of the key functional
domains of any SNARE-protein is either a transmembrane
domain or a lipidic membrane anchor enabling these pro-
teins to associate directly with membranes (review: 20,21).
Thus, when a SNARE is even slightly over-expressed, the
possibility of mis-localization of the tagged construct
to non-physiological compartments is a major concern.
Although it has been reported that over-expressed STX11
localizes to the recycling endosome in human CTL it is
not known whether this corresponds to localization of
the endogenous protein (12,22). Munc18-2 on the other
hand has no domains that suggest an ability to associate
with membranes independently of helper proteins. Indeed
over-expressed Munc18-2 constructs remain diffuse
cytoplasmic (23) unless a membrane-associated binding
partner such as STX11 is expressed in parallel (24).
We therefore assessed the distribution of endogenous
Munc18-2 and STX11 in CTL. Four new polyclonal
antibodies were raised against near full-length human
Munc18-2 and STX11 protein. By comparing immunoflu-
orescence microscopy (IF) in healthy donor (HD) CTL
versus FHL4 and FHL5 patient cells, lacking Munc18-2 or
STX11, we were able to determine specific staining and
now show the localization of endogenous Munc18-2 and
STX11 in human CTL. In order to do this we also report a
novel patient mutation in Munc18-2 that abolishes protein
expression, and used CTL from a previously reported
patient mutation lacking STX11. This approach allowed
us to define the endogenous localization of both proteins.
Our data reveal that endogenous Munc18-2 localizes
predominantly to the cytolytic granules, with low levels on
the plasma membrane, and is required for STX11 delivery
to the plasma membrane.
Results
FHL4 and FHL5 CTL validate STX11 and Munc18-2
antibody speciﬁcity
FHL4 CTL with a homozygous loss of the entire STX11
coding exon (AL135917:g.25561–44749_del, 25) and
FHL5 CTL with a homozygous deletion-insertion muta-
tion (c.1468_1470delCGGinsTGGACAGCCCTGGAC
AGGG p.R490WfsX95, UPN666), leading to a frameshift
from amino acid 490 onwards and predicting a premature
stop-codon were used to confirm the antibody specificities
(Figure 1A).
Western blottingwith theMunc18-2 and STX11 antibodies
5182 and 5412 showed a complete loss of Munc18-2 and
STX11 protein from the FHL4 and 5 CTL, respectively. As
described previously for other FHL5 patients (3,4) STX11
levels are reduced in the absence of Munc18-2 (Figure 1B).
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Figure 1: FHL4 and FHL5 patient CTL establish Syntaxin 11 and Munc18-2 antibody speciﬁcity. A) Schematic represen-
tation of the STX11 and Munc18-2 amino acid sequences indicating the effects of the homozygous mutations present in the FHL4
(847–1850) and FHL5 (UPN666) patient cells used in this study compared to healthy donor (HD). B) Western Blots on human CTL
lysates against Munc18-2 and STX11 using the two polyclonal rabbit antibodies 5182 and 5412. C) Percentage of P815 target cells
lysis (% killing) for HD (solid black line, squares) or FHL5 patient UPN666 CTL (dotted black line, triangles) at Effector:Target ratios
shown. CTL,10 days post restimulation. D) Granule release assay showing surface LAMP1 after 30minutes PMA-Ionomycin stimulation
of CTL from HD (solid black) and FHL5 patient UPN666 (dotted black line). Solid gray line: unstimulated HD CTL. CTL, 10 days post
restimulation.
The frameshift mutation in UPN666 has not been
described before. We therefore investigated the effects
of this novel mutation on CTL killing and degranulation
and found both to be reduced even after 2 weeks of culture
in the presence of IL-2 (Figure 1C,D). This stands in
contrast to several previously published FHL5 patient CTL
that did not show abnormal cytotoxicity in culture (26).
Endogenous Munc18-2 localizes to cytolytic granules
and the plasma membrane in human CTL
We tested both anti-Munc18-2 antibodies (5182 and
5184) by IF on HD as well as FHL5 CTL (Figure 2). In
HD derived CTL, both antibodies localized predom-
inantly to intracellular granules and a central puncta,
with low levels detected on the plasma membrane. We
subsequently focused on antibody 5182 because it pro-
vided a stronger signal. By staining HD and FHL5 patient
cells in parallel we confirmed that the granular and the
plasma membrane staining are specific to Munc18-2
(Figure 2A,B). Colocalization with LAMP1 (n= 158 HD
cells) and the cytolytic granule marker perforin (n= 119
HD cells) identified the predominant granular staining as
the cytolytic granules. Munc18-2 colocalized with LAMP1
on the limiting membrane of the granule (Figure 2C)
surrounding perforin (Figure 2D). This staining was lost
from FHL5 CTL (Figure 2A–D) while the central puncta,
identified as the centrosome by gamma-tubulin colocal-
ization, remained (data not shown). A weak cytoplasmic
staining could also be detected in HD cells, consistent with
a small pool of Munc18-2 dispersed throughout the cyto-
plasm. With six independent experiments revealing strong
granular staining inHDCTL, our experiments suggest that
endogenous Munc18-2 is localized to cytolytic granules
in CTL. Although some plasma membrane staining was
observed it was weaker and variable between experiments
(Figure 2A–D). When Munc18-2 was observed on the
1332 Trafﬁc 2015; 16: 1330–1341
Localization of Endogenous STX11 & Munc18-2 in CTL
Figure 2: Legend on Next page.
Trafﬁc 2015; 16: 1330–1341 1333
Dieckmann et al.
plasmamembrane an accumulation was seen at the leading
edge in 30% of cells (Figure 2A,B).
As Munc18-2 localized to cytolytic granules in CTL, we
asked whether this was maintained when granules polar-
ized toward target cells. Two-thirds of CTL-target con-
jugates showed granules clustered at the immunological
synapse, and in each case Munc18-2 remained associated
with the granules (Figure 2E, n= 63). Any plasma mem-
brane staining, remained equally distributed in all conju-
gates without accumulation at the synapse (Figure 2E).
Endogenous STX11 associates with the plasma
membrane accumulating at the leading edge of
human CTL
We next sought to determine whether STX11 localized
to the same cellular compartments as Munc18-2. Again,
both our custom-made STX11 antibodies (5412 and 5413)
showed the same staining pattern in CTL and one antibody
(5412) yielded considerably stronger signal.
In five independent experiments we compared STX11
staining with 5412 in HD cells (n= 328) and FHL4 control
cells (n= 312). We observed staining of the plasma mem-
brane exclusively in HD cells while punctate cytoplasmic
and centrosome staining was found in both HD and
FHL4 cells, suggesting that these signals were non-specific
(Figure 3A). It should be noted that as cells were fixed with
methanol any free cytoplasmic pool of STX11 would be
lost after fixation. Hundred percent of HD CTL showed
plasma membrane localization of STX11, with 30% show-
ing accumulation at the leading edge (Figure 3B). In
CTL-target conjugates, STX11 accumulated either across
or clustered at the immune synapse in ≤16% of conjugates
(Figure 3C). In contrast to Munc18-2 we did not observe
colocalization of STX11 with LAMP1 (Figure 3D).
Munc18-2 localization is independent of STX11
but in the absence of Munc18-2, STX11 is lost from
the plasma membrane
It has been suggested that Munc18-2 might act as a chap-
erone to transport STX11 to the plasma membrane as
observed for the Munc18/STX1A pair (7,8). Therefore,
we asked whether the localization of endogenous STX11
at the plasma membrane depends upon the presence
of Munc18-2 and vice versa. We performed parallel
Munc18-2 and STX11 staining in HD, FHL4 and FHL5
cells in three independent experiments and co-stained
with LAMP1 or CD8 in order to assess potential effects on
colocalization with these markers.
As observed previously, we found strong Munc18-2
staining on granules and weaker staining on the plasma
membrane in HD cells (n= 265) but no Munc18-2 stain-
ing on FHL5 cells (n= 263). Centrosomal staining was
non-specific as it was present in both HD and patient cells.
Munc18-2 staining in FHL4 cells (n= 252) resembled
staining in HD cells, indicating that Munc18-2 localization
was not affected by the absence of STX11. In contrast,
FHL5 CTL (lacking Munc18-2) completely lost the plasma
membrane STX11 localization seen in HD CTL (Figure 4),
confirmed by colocalization with the T cell plasma mem-
brane protein, CD8 (Figure 5). These results support a role
for Munc18-2 in STX11 stability and are consistent with
Figure 2: Endogenous Munc18-2 localizes predominantly to cytolytic granules in human CTL. A) Immunoﬂuorescence
microscopy showing localization of Munc18-2 (antibody 5182) in healthy donor (HD) and FHL5 CTL (UPN666). White arrowheads:
leading edge. B) Quantitation of Munc18-2 antibody staining from 6 independent experiments: HD (white, n= 397) and FHL5 (gray,
n= 374). Gran: granular staining, PM: plasma membrane staining, hatched bar= HD CTL with an accumulation of Munc18-2 at the
leading edge. Shown is the mean with standard deviation, *** indicates a signiﬁcant difference with p< 0.0001, two-tailed students
t-test (unpaired), 95% conﬁdence limits. C) Co-staining for Munc18-2 (green) and LAMP1 (red) in three independent experiments
comparing HD and FHL5 CTL (n= 158 each). Yellow lines (i) and (ii) were drawn via the IMAGEJ line tool (linewidth: 3 pixel) to obtain
Munc18-2 and LAMP1 intensity proﬁles. Imaris display adjustments optimized for granular signal. D) Co-staining of a CTL-P815
conjugate for Munc18-2 (green) and perforin (red, exclusively expressed in CTL). The white arrowhead indicates a perforin core
surrounded by Munc18-2 (n= 119 HD, 2 independent experiments). E) Co-staining of a CTL-P815 conjugate for Munc18-2 (green) and
CD8 (red) showing polarization of granule-associated Munc18-2 toward the synapse (n= 63). All images show single confocal planes.
Scale bars: 5 μm.
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Figure 3: Endogenous STX11 is on the plasma membrane of human CTL. A) Localization of STX11 in healthy donor (HD) and
FHL4 patient 847–1850 CTL using antibody 5412. White arrowheads: leading edge. B) Percentage of cells with plasma membrane
staining for HD (white, n= 328) and FHL4 (black, n= 312) CTL using antibody 5412. PM: plasmamembrane staining, hatched bar= HD
CTL with an accumulation of STX11 at the leading edge. Results shown as mean from ﬁve independent experiments with standard
deviation, *** indicate a signiﬁcant difference with p<=0.0001, two-tailed students t-test (unpaired), 95% conﬁdence limits. C)
STX11 staining using antibody 5412 in HD CTL-target conjugates illustrating STX11 accumulation at the synapse (5 experiments,
n= 128). D) Co-staining for anti-STX11 5412 (green) and LAMP1 (red) in HD cells (2 experiments, n= 135). Yellow lines (i) and (ii)
were drawn via the IMAGEJ line tool (linewidth: 3 pixel) to obtain STX11 and LAMP1 intensity proﬁles. All images show single confocal
planes. Scale bars: 5 μm.
a role for Munc18-2 in chaperoning STX11 to the plasma
membrane.
Discussion
Munc18-2 and STX11 play essential roles in secretion from
CTL and NK cells. Mutations in the genes encoding these
two proteins give rise to FHL, a profound immunodefi-
ciency that can be cured only by bonemarrow transplanta-
tion. Functional studies have shown that these proteins play
a role in secretion (2–4), but do not reveal at which stage in
the secretory pathway they are required. In order to iden-
tify the sites of action of Munc18-2 and STX11 we asked
where the endogenous proteins were localized in CTL.
There are two well-acknowledged problems with establish-
ing the cellular localization of SNARE and associated
Munc18 proteins: over-expression often results in
mis-localization because SNARE component proteins can
recombine promiscuously and levels of binding partners
become limiting (7,20,27). Furthermore, the multitude of
homologous proteins (15 syntaxins; 3 Munc18-proteins)
means that it can be difficult to determine the specificity of
antibody binding for any single protein. In order to over-
come these difficulties, we investigated the localization of
endogenous STX11 andMunc18-2 in humanCTL through
the use of novel antibodies raised against (near) full-length
human Munc18-2 and STX11 protein. Importantly, the
use of patient CTL lacking STX11 (FHL4) and Munc18-2
(FHL5) allowed us to establish the specificity of staining.
Our results demonstrate that endogenous Munc18-2 is
localized predominantly on secretory lysosomes of CTL
although lower levels are observed on the plasma mem-
brane, where STX11 is found, raising the possibility that
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Figure 4: Munc18-2 localization is independent of STX11 but in the absence of Munc18-2, STX11 is lost from the
plasma membrane. Localization of endogenous Munc18-2 and STX11 in CTL from healthy donor (HD) (n= 265), FHL4 (847–1850,
n= 252) and FHL5 (UPN666, n= 263) using antibodies 5182 and 5412 respectively. All images show single confocal planes and
represent three independent experiments. Scale bars: 5 μm.
Munc18-2 might transit the plasma membrane and deliver
STX11 to this site.
Previous studies in CTL and NK cells have examined the
localization of over-expressed, tagged constructs of these
proteins (11,12,22,24,28) or using antibodies raised against
peptide or mouse epitopes in human CTL (13,29). These
studies suggested many possible localizations in CTL, with
Munc18-2 diffusely cytoplasmic (24), on dense puncta (13)
or associated with cytolytic granules (24) and STX11 on
distinct cytoplasmic puncta (11,12,22,28,29) colocalizing
with CD3 and granzyme B (12) but not perforin (28,29)
and/or associated with the plasma membrane (12,24).
Our localization of endogenous STX11 staining confirms
the plasma membrane component of the localiza-
tion observed when TFP-STX11 and GFP-STX11 was
expressed in human CTL and YTS NK cells, respectively
(12,24). However, we do not observe the additional local-
ization of STX11 on vesicular structures observed when
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Figure 5: STX11 colocalizes with CD8 at the plasma membrane. Co-staining for anti-STX11 5412 (green) and plasma
membrane marker CD8 (red) in healthy donor (HD) (n= 149, 4 experiments), FHL4 (847–1850, n= 144, 4 experiments) and FHL5
(UPN666, n= 56, 1 experiment) CTL. Yellow lines (i) and (ii) were drawn via the IMAGEJ line tool (linewidth: 15 pixel) to obtain STX11
and CD8 intensity proﬁles. All images show single confocal planes. Scale bars: 5 μm.
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STX11 is over-expressed (12,22,24,28) or with previous
antibody localizations (13,29). Although vesicular staining
was observed in several studies, there was little consensus
over the identity of this compartment. Recent reports
based on over-expressed TFP-STX11 colocalization with
mCherry-Rab11a propose a model by which STX11 is
only delivered to the plasma membrane immediately prior
to granule fusion via VAMP8-mediated fusion of the recy-
cling endosome (12,22). In the present study, we show that
there is a steady-state localization of endogenous STX11
on the plasma membrane, which requires Munc18-2 for
its delivery to this site.
Interestingly in a previous study the diffuse cytoplasmic
GFP-Munc18-2 localization changed to a vesicular colo-
calization with mcherry-Munc18-2 when both Munc18-2
and STX11 were over-expressed, demonstrating the
inter-dependence of these two proteins and the impor-
tance of determining the endogenous localization of these
proteins with physiological expression levels (24).
The localization of Munc18-2 on cytolytic granules in CTL
that we observe matches the endogenous Munc18-2 stain-
ing observed on the secretory granules of mast cells (18,30)
and in neutrophils (31). Intriguingly these granules are all
secretory lysosomes, suggesting thatMunc18-2 localizes to
this compartment in immune cells.
We found the distribution of Munc18-2 to be the same in
HD cells and STX11-deficient FHL4-cells. This suggests
that Munc18-2 does not depend on STX11 for its associ-
ation with granule membranes and the plasma membrane
and could be explained by Munc18-2 associating with
an alternative SNARE-protein in the absence of STX11.
Hackmann et al. (25) demonstrated that the N-terminal
peptide of the STX11 homologue Syntaxin3 (STX3) binds
Munc18-2 in vitro (albeit with 20 times lower affinity com-
pared to the STX11 peptide) and that STX3 expression
is upregulated through IL-2 culture of human NK cells,
a culture condition that has previously been reported to
partially restore granule release and killing through FHL4
and five NK cells and CTL (2–4,32). Hackmann et al.
furthermore showed STX3 re-localized from intracellu-
lar vesicles to the plasma membrane in STX11 deficient
CTL. These findings suggest STX3 as one likely candi-
date for interaction with Munc18-2 at the granule and
plasma membrane in the absence of STX11. Conversely,
STX11 is lost from the plasma membrane in FHL5 patient
cells lacking Munc18-2. STX11 thus appears to require
Munc18-2 either to reach the plasma membrane or to
remain stably associated with it, although we cannot rule
out the possibility that Munc18-2 might stabilize STX11
at an earlier stage during its biosynthesis. Either way,
Munc18-2 appears to be required to build up a steady-state
pool of STX11 on the plasma membrane of CTL.
Two observations invite further speculation on additional
roles for both proteins: STX11 readily accumulates at the
leading edge of migrating CTL but we only rarely observed
an accumulation at the immune synapse. Fusion of the
small number of cytolytic granules that is needed to elim-
inate a target may not necessarily require a high density of
SNARE proteins. At the leading edge of a migrating cell,
however, a high number of vesicles that deliver migratory
or target sensing factors to the plasmamembranemay need
to be turned over (33) and it is tempting to speculate that
STX11may be involved in these processes. Similarly, based
on the fact that only Munc18-2 (but not STX11) localized
toCTL granules it is possible thatMunc18-2may play addi-
tional roles on this compartment as previously suggested
for granular Munc18-2 in mast cells (18).
Materials and Methods
Cells
Patient UPN666 presented at the age of 1 month with full-blown HLH
(fever, splenomegaly, bi-cytopenia, low plasma levels of fibrinogen, high
levels of triglycerides and ferritin). Functional study showed defective
GRA results; sequencing of the Syntaxin binding protein 2 (Munc18-2)
(STXBP2) gene revealed a homozygous deletion-insertion muta-
tion (c.1468_1470delCGGinsTGGACAGCCCTGGACAGGG p.R490
WfsX95), leading to a frameshift at amino acid 490 and predicting a
premature stop-codon 95 amino acids later; thus, FHL5 was diagnosed.
Ethical approval was obtained in accordance with the standards of the
Declaration ofHelsinki. A bulk CD8 line (CTL) FHL4 patient (847–1850)
was described previously (25). Bulk CD8+ cells from the FHL5 patient
(UPN666) were isolated by negative selection from peripheral blood
mononuclear cells (PBMCs) using the Dynabeads Untouched Human
CD8 T-cell purification kit from Invitrogen. HD CTL were from donor
434–722.
Cell culture
CTL were cultured at 37∘C in a humidified atmosphere with 8–10% CO2
in RPMI 1640, 2mM L-glutamine, 1mM sodium pyruvate, 0.9 M sodium
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bicarbonate, 50 μM beta-mercaptoethanol (Invitrogen-GIBCO), 5%
humanAB-Serum (SeraLab) and recombinant human IL-2 (∼100U/mL).
CTL were stimulated every 3–4 weeks using irradiated PBMCs isolated
from buffy coats in the presence of PHA. Whole human blood was
collected from HDs with informed consent from individuals and pre-
vented from coagulation by addition of sterile sodium citrate. PBMCs
were isolated by Ficoll-Paque™ (GE Healthcare) gradient centrifugation,
irradiated at 3000 radiation absorbed dose (rad) of gamma rays and
seeded at a 1:1 ratio with human CTL in a 24-well plate and a final
concentration of 1 μg/mL PHA (Roche). CTL were imaged 10–15 days
post stimulation, when maximal killing capacity was reached. Purity
of CTL populations (80–99%) was confirmed by flow cytometry with
anti-human CD8-allophycocyanin (APC) [MEM-31] and anti-human
CD4-R-phycoerythrin (PE) [MEM-241] antibodies (both Abcam) prior
to use.
Antibodies and reagents
Polyclonal rabbit antibodies were raised against full-length human
Munc18-2 (5182 and 5184) and STX11ΔCys-GST (5412 and 5413)
as previously described (25). Other antibodies were sourced: mouse
anti-human LAMP1 [H4A3] (Iowa University Hybridoma cell bank),
mouse anti-human CD8 [UCHT4] (Sigma-Aldrich, C7423), mouse
anti-human perforin [δG9] (BD Pharmingen, 556434), mouse anti-beta
actin [AC-15] (Sigma-Aldrich, A5441), mouse anti-human LAMP1-PE
[H4A3] (eBioscience, 12–1079), mouse anti-human CD8-APC
[MEM-31] (Abcam, ab26004), mouse anti-human CD4-PE [MEM-241]
(Abcam, ab18282). Secondary antibodies goat anti-rabbit-AF488
(A11034, highly cross-adsorbed) and goat anti-mouse-AF568 (A11031,
highly cross-adsorbed) and Hoechst nuclear stain 33342 were from Invit-
rogen. HRP-conjugated secondary antibodies used for immunoblotting
were goat anti-rabbit IgG (Jackson, 111-035-144) and goat anti-mouse
IgG (Jackson, 113-035-146). Ionomycin and PMA were obtained from
Sigma-Aldrich.
Immunoblotting
CTL were washed 2–3× in ice-cold sterile PBS. Cells (4× 107/mL) were
lysed in lysis buffer (50mM Tris–HCl, 100mM NaCl, 5mM Mg Cl2, 1%
Triton X-100, pH 7.6) supplemented with Protease Inhibitor Cocktail
(Roche), loaded in SDS Sample Buffer [2× sample buffer was: 187.5mM
Tris–HCl (pH 6.8); 6% v/v SDS; 30% v/v glycerol; 0.03% w/v bromophe-
nol blue (BioRad)] on 4–12% NuPage Bis-Tris Gels under reducing con-
ditions [5% beta-mercaptoethanol (Sigma)] in MES buffer (Invitrogen)
and transferred for 90min at 300mA to Hybond-C Extra nitrocellu-
lose membrane (Amersham Biosciences) using transfer buffer (25mM
Tris, 192mM glycine, 25% methanol). Membranes were blocked in PBS,
5% Milk (Marvel semi-skimmed) and 0.05% Tween-20 (Sigma-Aldrich).
Incubationwith primary antibody in blocking buffer was 1 h at room tem-
perature. Membranes were washed 3× for 10min in PBS-Tween solution
and incubated with HRP-coupled secondary antibody in blocking buffer
for 30–45min at room temperature. Membranes were washed as before
followed by an additional wash in PBS for 10min. Blots were developed
using ECLWestern Blotting solutions (Amersham).
Immunoﬂuorescence microscopy and confocal imaging
CTL were washed into pre-warmed serum-free RPMI medium and
allowed to settle onto hydrophobic multiwell slides (50 000 cells/well in
50 μL medium) for 20–25min at 37∘C. For conjugates P815 target cells
were mixed at 1:1 ratio with human CTL , with 1 μg/mL PHA in RPMI at
4× 106 cells/mL concentration, incubated in suspension for 5min, diluted
to 1× 106 cells/mL, plated onto glassmultiwell slides (Hendley), and incu-
bated for a further 20–25min at 37∘C to adhere to the glass. Cells were
fixed with ice-cold methanol for 5min on ice (except Figure 2C were cells
were fixed in PFA for 20min at room temperature), washed extensively in
PBS prior to blocking in IF blocking buffer [1% BSA (Sigma-Aldrich) in
PBS] for 60min at room temperature. All antibodies were diluted into IF
blocking buffer. Sampleswere incubatedwith primary antibodies for 1 h at
room temperature in a humidified environment, washed extensively and
incubated with secondary antibody for 30–40min in the dark. Samples
were washed with blocking buffer and nuclei were stained with Hoechst
diluted (1:25 000) in PBS for 7–10min at room temperature. Samples
werewashed prior tomountingwith non-settingmountingmedium (Vec-
tashield, Vectalabs) and sealed with clear nail varnish.
Samples were imaged at room temperature with an Andor Revolution
Spinning disk system with CSU-X1 spinning disk (Yokogawa), 512× 512,
16 μm2-pixel camera (iXon, Andor) IX81 microscope (Olympus) using
the 60× or 100× objective (numerical aperture 1.45) and 2.5× cam-
era adapter and with lasers exciting at 405, 488 and 561 nm. Images
were acquired using IQ2 (Andor) and processed using IMARIS software
(Bitplane).
Cytotoxicity assay
Cytotoxicity was determined with the CytoTox 96Non-Radioactive Cyto-
toxicity Assay (Promega) following manufacturers instructions. In brief:
CTLwerewashed 2× in killing assaymedium (RPMI 1640mediumminus
phenol red, 2% fetal calf serum, FCS) and added in serial dilution to
a round-bottomed 96-well plate to achieve titrated effector:target (E:T)
ratios. P815 target cells were washed 2× and resuspended in killing assay
media at 1× 105 cells/mL. Mouse anti-human CD3ε antibody [UCHT-1]
(BD Biosciences, 555330) was added to the target cells at a concentration
of 1 μg/mL (leading to a final concentration of 0.5 μg/mL upon addition
of target cells to CTL suspension). Plates were incubated at 37∘C. The
absorbance of the supernatants at 490 nmdetermined the release of lactate
dehydrogenase and percentage cytotoxicity after 2.5 h.
Granule release assay
CTL of about 2–5× 105 were plated in 100 μL human CTL
medium+ 1.6 μL anti-hLAMP1-PE antibody per well on a flat bot-
tom 96-well plate (unstained and CD8+ single stained samples were
plated in CTL medium only),100 μL human CTL medium containing
1 μg/mL Ionomycin plus 4 μM PMA or DMSO only were added to each
well and the plate was incubated at 37∘C. At each time point cells were
transferred to a pre-cooled round-bottom 96-well plate and spun down
at 493× g for 6min at 5 ∘C. The medium was discarded, the cells were
resuspended in 200 μL FACS buffer (PBS, 1% HI FCS, Biosera) per
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well and stored on ice in the dark until all time points were collected.
Cells were pelleted, resuspended in FACS buffer plus anti-CD8-APC
antibody (50 μL per well) and incubated for 30min on ice in the dark.
Cells were washed 1× and resuspended in 160 μL FACS buffer per well.
Cells were analyzed using a FACSCalibur instrument (Becton Dickson)
and FLOWJO software where gates were set as follows: Live cells (based
on forward versus side scatter), CD8+ T-cells (based on APC staining),
CD8+/LAMP1+ T-cells based on PE-staining. The use of PE and APC
fluorophores meant that no compensation was necessary during data
acquisition. % of Max is ‘the number of cells in each bin divided by the
number of cells in the bin that contains the largest number of cells’. Bins
are defined as ‘numerical ranges for the parameter on the X axis’ (FlowJo
manual, http://www.flowjo.com/v6/html/faq.html#2.4.4).
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